Ticker Details
AnaptysBio, Inc. AnaptysBio Inc is a biotechnology company. The company is engaged in developing first-in-class antibody product candidates focused on unmet medical needs in inflammation and immuno-oncology. Its product include ANB020 and ANB019.
IPO Date:	January 26, 2017
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$1.5B
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$0.96 | 2.65%
Avg Daily Range (30 D):	$1.27 | 2.62%
Avg Daily Range (90 D):	$1.09 | 2.58%

Institutional Daily Volume
Avg Daily Volume:	.31M
Avg Daily Volume (30 D):	.36M
Avg Daily Volume (90 D):	.41M

Trade Size
Avg Trade Size (Sh.):	73
Avg Trade Size (Sh.) (30 D):	51
Avg Trade Size (Sh.) (90 D):	56

Institutional Trades
Total Institutional Trades:	3,172
Avg Institutional Trade:	$1.73M
Avg Institutional Trade (30 D):	$2.21M
Avg Institutional Trade (90 D):	$2.53M
Avg Institutional Trade Volume:	.05M
Avg Institutional Trades (Per Day):	1

Market Closing Trades
Avg Closing Trade:	$1.74M
Avg Closing Trade (30 D):	$2.78M
Avg Closing Trade (90 D):	$2.54M
Avg Closing Volume:	53.37K

News

Jan 8, 2026 @ 11:00 PM Anaptys Files Motion to Dismiss Tesaro’s Cl... Source: Na

Nov 21, 2025 @ 1:48 PM GSK Unit Tesaro Sues AnaptysBio, Threatening Key C... Source: Vandana Singh

Nov 21, 2025 @ 8:50 AM Anaptys Initiates Litigation Against Tesaro, a GSK... Source: Anaptysbio

Sep 29, 2025 @ 9:06 PM 12 Health Care Stocks Moving In Monday's After-Mar... Source: Benzinga Staff Writer

Apr 14, 2025 @ 5:00 PM Psoriasis Market Outlook in the 7MM Through 2034: ... Source: Delveinsight

Financials
	TTM	Q3 2025	Q2 2025
Basic EPS		$.54	$-1.34
Diluted EPS		$.52	$-1.34
Revenue		$76.32M	$22.26M
Gross Profit
Net Income / Loss		$15.11M	$-38.63M
Operating Income / Loss		$34.7M	$-26.17M
Cost of Revenue
Net Cash Flow		$65.54M	$-54.34M
PE Ratio